Emcure Pharmaceuticals’ shares had an excellent Dalal Street debut on Wednesday when they were listed on the NSE at Rs 1,325.05, which is 31.45% more than the stock’s issue price of Rs 1,008. Similarly, the stock was also listed on the BSE at the same price and premium.

However, the actual listing has followed the predicted lines for investors. Emcure Pharma’s shares were trading at a grey market premium (GMP) of Rs 300 per share prior to the IPO, implying a 30% increase in value for investors.

Emcure Pharma’s IPO was open for bidding between July 3 and July 5. The Pune-based pharma firm issued its shares at a price range of Rs 960-1,008 per share with a lot size of 14 shares. With its primary offering, which included an offer-for-sale (OFS) of up to 79,36,507 shares and a new share sale of Rs 800 crore, the firm raised Rs 1,952.03 crore.

Established in 1981, Emcure Pharma is a homegrown pharmaceutical company that creates, produces and distributes a wide range of pharmaceutical products worldwide, covering several significant therapeutic areas. The firm operates thirteen manufacturing facilities across India.

Disclaimer: The information provided in this article is for informational purposes only and should not be considered as financial advice. The data and figures presented are based on publicly available information and may be subject to change. Before making any investment decisions, it is recommended to conduct thorough research, consult with financial advisors, and consider your individual investment goals and risk tolerance. The author and publisher of this article do not assume any responsibility for any investment decisions made based on the information provided.

In a strong show of investor confidence, two initial public offerings (IPOs) launched on Monday have surpassed expectations, both becoming oversubscribed within hours of opening.

Bansal Wire Industries Ltd, a leading manufacturer in the wire industry, saw its Rs. 745 crore IPO oversubscribed 1.86 times by the end of its first day. The offering, which opened on July 3rd and will close on July 5th, provides investors with lots of 58 shares at Rs. 14,094 per lot.

Meanwhile, pharmaceutical giant Emcure Pharmaceuticals Ltd also made waves with its Rs. 1,952.03 crore IPO. The company’s offering, with a bid price range of Rs. 960-1,008 and lot size of 14 shares, was oversubscribed 1.32 times by market close on Monday.

“The overwhelming response to both IPOs signals a robust appetite for quality offerings in the market,” said a market analyst who wished to remain anonymous. “Investors seem particularly drawn to companies with strong fundamentals and growth potential.”

Both IPOs will remain open until July 5th. Share allotment for successful applicants is scheduled for July 8th, with the stocks set to list on major exchanges on July 10th.

As the IPO market heats up, all eyes will be on how these stocks perform upon listing. The strong initial response suggests that both Bansal Wire and Emcure Pharmaceuticals may be poised for a strong debut.

Investors and market watchers alike will be closely monitoring these IPOs in the coming days, as they could set the tone for future offerings in what has already been a busy year for the Indian IPO market.

A busy week is ahead for IPO investors as two firms are scheduled to debut on Dalal Street. Emcure Pharmaceuticals and Bansal Wire Industries, two homegrown companies, plan to launch their public offerings to collectively raise around ₹2,700 crore via the initial public offering (IPO) route. Ghaziabad-based Bansal Wire Industries aims to raise ₹745 crore via IPO, while Pune-based Emcure Pharmaceuticals hopes to garner ₹1,952 crore through public listing of shares on domestic exchanges.

Emcure Pharma

With an IPO price range of ₹960–1,008 per share, the Pune-based pharma company hopes to raise ₹1,952.03 crore at the top end of the issue price. The three-day IPO will begin for subscriptions on July 3 and end on July 5, with the anchor book opening for one day on July 2. The tentative date for listing shares on stock markets is July 10, 2024.

The issue consists of an offer for sale (OFS) of 1.14 crore shares, totalling ₹1,152.03 crores and a fresh issuance of 0.79 crore equity shares, worth ₹800 crore.

Retail investors will have to invest ₹14,112 to purchase a minimum lot size of 14 shares for an application.

It has reserved half of the issue size for qualified institutional purchasers, 35% for retail investors and the remaining 15% for non-institutional investors. Additionally, 1,08,900 equity shares have been reserved for its staff, who will be offered at a discount to issue price.

The book running lead managers for the Emcure Pharma IPO are Axis Capital Limited, J.P. Morgan India Private Limited, Jefferies India Private Limited and Kotak Mahindra Capital Company Limited. The issue’s registrar is Link Intime India Private Ltd.

Bansal Wire Industries

The Bansal Group’s flagship company, located in Ghaziabad, is scheduled to debut on Dalal Street on July 3  with its ₹745 crore IPO. The company has set a price band of ₹243-256 per share for its IPO, which will conclude on July 5. The anchor book will be open for one day on June 2, with the shares slated to launch on July 10.

The steel wires manufacturer’s post-listing market capitalization is ₹3,262 crore, with a completely fresh issue of ₹745 crore.

The firm aims to utilize the IPO proceeds to repay loans availed by itself and its subsidiaries, as well as to support the company’s working capital requirements and other corporate purposes.